The SOS1:KRAS inhibitor BI-3046, developed by Boehringer Ingelheim, has been evaluated in vivo in NSCLC and CRC PDX models specifically in combination with trametinib (MEK inhibitor). This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.